Compare Bristol-Myers Squibb Co (BMY) vs Gogoro Inc (GGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Gogoro Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.83 (market cap $116.30B), while Gogoro Inc trades at $3.93 (market cap $76.98M). The key difference: Bristol-Myers Squibb Co is far larger — about 1510.8× Gogoro Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.
| BMY | GGR | |
|---|---|---|
Market Cap | $116.30B | $76.98M |
Sector | Health | Technology |
52-Week High | $62.37 | $7.89 |
52-Week Low | $42.60 | $2.74 |
Enterprise Value | $152.24B | $379.42M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
GGR trades at $3.88, up 0.78% on the day, while showing bearish technical signals with a negative net income margin of -24.68% and ROE of -50.38% for 2025. The company reported revenue of $281.48M but a net loss of $79.97M, though cash flow from operations improved to $35.90M. Recent news highlights a private placement and Q1 2026 results emphasizing margin improvement and growth plans.
Outlook remains challenged by persistent losses and negative profitability metrics, offset by operational discipline and subscriber growth. Key risks include execution on profitability, competitive pressures, and cash flow sustainability. Analysts are neutral with 100% hold ratings, reflecting cautious optimism amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
